IQVIA Holdings Inc., a leading enabler for pharmaceutical and healthcare companies, has seen its stock price increase to $191.15 as of August 22nd. With a focus on accelerating drug development and commercialization, IQVIA’s different business segments contribute to its success. Despite a recent drawdown due to biotech funding challenges, IQVIA’s fundamentals remain strong, with a backlog of $32.1 billion expected to convert into revenue over the next 12 months. Resolving legal disputes and entering collaborations with Veeva also position IQVIA for growth and expansion in the future.

Read more at Yahoo Finance: IQVIA Holdings Inc. (IQV): A Bull Case Theory